Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion

References

1. 1.↵
   2. Louis DN,
   3. Perry A,
   4. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
2. 2.↵
   2. Louis DN,
   3. Perry A,
   4. Wesseling P, et al

   . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
3. 3.↵
   2. Horbinski C,
   3. Nikiforova MN,
   4. Hobbs J, et al

   . The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas. J Neuropathol Exp Neurol 2012;71:73–82 doi:10.1097/NEN.0b013e318240fa65 pmid:22157622

   CrossRefPubMed
4. 4.↵
   2. Horbinski C

   . What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol 2013;125:621–36 doi:10.1007/s00401-013-1106-9 pmid:23512379

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Lasocki A,
   3. Tsui A,
   4. Tacey MA, et al

   . MRI grading versus histology: predicting survival of World Health Organization grade II–IV astrocytomas. AJNR Am J Neuroradiol 2015;36:77–83 doi:10.3174/ajnr.A4077 pmid:25104288

   Abstract/FREE Full Text
6. 6.↵
   2. Lasocki A,
   3. Anjari M,
   4. Örs Kokurcan S, et al

   . Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review. Neuroradiology 2021;63:353–62 doi:10.1007/s00234-020-02532-7 pmid:32840682

   CrossRefPubMed
7. 7.↵
   2. Broen MPG,
   3. Smits M,
   4. Wijnenga MMJ, et al

   . The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower grade glioma: a validation study. Neuro Oncol 2018;20:1393–99 doi:10.1093/neuonc/noy048 pmid:29590424

   CrossRefPubMed
8. 8.↵
   2. Lasocki A,
   3. Gaillard F,
   4. Gorelik A, et al

   . MRI features can predict 1p/19q status in intracranial gliomas. AJNR Am J Neuroradiol 2018;39:687–92 doi:10.3174/ajnr.A5572 pmid:29519793

   Abstract/FREE Full Text
9. 9.↵
   2. Patel SH,
   3. Poisson LM,
   4. Brat DJ, et al

   . T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23:6078–85 doi:10.1158/1078-0432.CCR-17-0560 pmid:28751449

   Abstract/FREE Full Text
10. 10.↵
    2. Park SI,
    3. Suh CH,
    4. Guenette JP, et al

    . The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis. Eur Radiol 2021;31:5289–99 doi:10.1007/s00330-020-07467-4 pmid:33409784

    CrossRefPubMed
11. 11.↵
    2. Saito T,
    3. Muragaki Y,
    4. Maruyama T, et al

    . Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas. Brain Tumor Pathol 2016;33:175–82 doi:10.1007/s10014-016-0249-5 pmid:26849373

    CrossRefPubMed
12. 12.↵
    2. Lasocki A,
    3. Buckland ME,
    4. Drummond KJ, et al

    . Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas. Neuroradiology 2022;64:2295–305 doi:10.1007/s00234-022-02975-0 pmid:35606654

    CrossRefPubMed
13. 13.↵
    2. Lasocki A,
    3. Rosenthal MA,
    4. Roberts-Thomson SJ, et al

    . Neuro-oncology and radiogenomics: time to integrate? AJNR Am J Neuroradiol 2020;41:1982–88 doi:10.3174/ajnr.A6769 pmid:32912874

    Abstract/FREE Full Text
14. 14.↵
    2. Patel SH,
    3. Batchala PP,
    4. Mrachek EK, et al

    . MRI and CT identify isocitrate dehydrogenase (IDH)-mutant lower-grade gliomas misclassified to 1p/19q codeletion status with fluorescence in situ hybridization. Radiology 2020;294:160–67 doi:10.1148/radiol.2019191140 pmid:31714193

    CrossRefPubMed
15. 15.↵
    2. Brandner S,
    3. McAleenan A,
    4. Jones HE, et al

    . Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: a comprehensive meta-analysis based on a Cochrane systematic review. Neuropathol Appl Neurobiol 2022;48:e12790 doi:10.1111/nan.12790 pmid:34958131

    CrossRefPubMed
16. 16.↵
    2. Jenkins RB,
    3. Blair H,
    4. Ballman KV, et al

    . A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852–61 doi:10.1158/0008-5472.CAN-06-1796 pmid:17047046

    Abstract/FREE Full Text
17. 17.↵
    2. Bhandari AP,
    3. Liong R,
    4. Koppen J, et al

    . Noninvasive determination of IDH and 1p19q status of lower-grade gliomas using MRI radiomics: a systematic review. AJNR Am J Neuroradiol 2021;42:94–101 doi:10.3174/ajnr.A6875 pmid:33243896

    Abstract/FREE Full Text
18. 18.↵
    2. Kalaroopan D,
    3. Lasocki A

    . MRI-based deep learning techniques for the prediction of isocitrate dehydrogenase and 1p/19q status in grade 2-4 adult gliomas. J Med Imaging Radiat Oncol 2023;67:492–98 doi:10.1111/1754-9485.13522 pmid:36919468

    CrossRefPubMed
19. 19.↵
    2. Johnson DR,
    3. Diehn FE,
    4. Giannini C, et al

    . Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI. AJNR Am J Neuroradiol 2017;38:678–84 doi:10.3174/ajnr.A5070 pmid:28126746

    Abstract/FREE Full Text
20. 20.↵
    2. Kim JW,
    3. Park CK,
    4. Park SH, et al

    . Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 2011;82:224–27 doi:10.1136/jnnp.2009.178806 pmid:20587495

    Abstract/FREE Full Text
21. 21.↵
    2. Cui Y,
    3. Ma L,
    4. Chen X, et al

    . Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma. J Neurooncol 2014;119:377–85 doi:10.1007/s11060-014-1490-6 pmid:24874469

    CrossRefPubMed
22. 22.↵
    2. Thust SC,
    3. Hassanein S,
    4. Bisdas S, et al

    . Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. Eur Radiol 2018;28:3779–88 doi:10.1007/s00330-018-5351-0 pmid:29572636

    CrossRefPubMed
23. 23.↵
    2. Darlix A,
    3. Deverdun J,
    4. Menjot de Champfleur N, et al

    . IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. J Neurooncol 2017;133:37–45 doi:10.1007/s11060-017-2421-0 pmid:28434111

    CrossRefPubMed
24. 24.↵
    2. Delfanti RL,
    3. Piccioni DE,
    4. Handwerker J, et al

    . Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. J Neurooncol 2017;135:601–09 doi:10.1007/s11060-017-2613-7 pmid:28871469

    CrossRefPubMed
25. 25.↵
    2. Hyare H,
    3. Rice L,
    4. Thust S, et al

    . Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status. Eur J Radiol 2019;114:120–27 doi:10.1016/j.ejrad.2019.03.003 pmid:31005161

    CrossRefPubMed
26. 26.↵
    2. Park YW,
    3. Han K,
    4. Ahn SS, et al

    . Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. AJNR Am J Neuroradiol 2018;39:37–42 doi:10.3174/ajnr.A5421 pmid:29122763

    Abstract/FREE Full Text
27. 27.↵
    2. Lev MH,
    3. Ozsunar Y,
    4. Henson JW, et al

    . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214–21 pmid:14970020

    PubMedWeb of Science
28. 28.↵
    2. Xing Z,
    3. Yang X,
    4. She D, et al

    . Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. AJNR Am J Neuroradiol 2017;38:1138–44 doi:10.3174/ajnr.A5171 pmid:28450436

    Abstract/FREE Full Text
29. 29.↵
    2. Lasocki A,
    3. Buckland ME,
    4. Molinaro T, et al

    . Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas. Neuroradiology 2023;65:1215–23 doi:10.1007/s00234-023-03175-0 pmid:37316586

    CrossRefPubMed
30. 30.↵
    2. Vogazianou AP,
    3. Chan R,
    4. Bäcklund LM, et al

    . Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol 2010;12:664–78 doi:10.1093/neuonc/nop075 pmid:20164239

    CrossRefPubMed
31. 31.↵
    2. Thiessen B,
    3. Maguire JA,
    4. McNeil K, et al

    . Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 2003;64:271–78 doi:10.1023/a:1025689004046 pmid:14558604

    CrossRefPubMed